Sunshine Biopharma Inc SBFM.OQ SBFM.O is expected to show a rise in quarterly revenue when it reports results on August 14 (estimated) for the period ending June 30 2025
The Fort Lauderdale Florida-based company is expected to report a 20.4% increase in revenue to $11.2 million from $9.3 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Sunshine Biopharma Inc is for a loss of 11 cents per share.
The one available analyst rating on the shares is "buy".
The average consensus recommendation for the pharmaceuticals peer group is also "Buy".
Wall Street's median 12-month price target for Sunshine Biopharma Inc is $7.00, about 79.6% above its last closing price of $1.43
This summary was machine generated August 12 at 20:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)